Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes new pharmaceutical products for the treatment of neurological and endocrine related diseases and disorders. The company’s products help to treat disease conditions such as endometriosis, anxiety, depression, pain, and other neurological and endocrine related diseases and disorders. The lead candidates of the company include elagolix (Phase III), a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis; INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders completed its Phase III clinical trial; and Opicapone (Phase III), a catechol-o-methyltransferase inhibitor for Parkinson’s disease patients. Other products in the pipeline include NBI-640756 and NBI-74788 both in Phase I. Neurocrine is headquartered in San Diego, California, the US.
Neurocrine Biosciences Inc Key Recent Developments
Feb 14,2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
Jan 06,2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
Dec 21,2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
Nov 02,2016: Neurocrine Biosciences Reports Third Quarter 2016 Results
Aug 03,2016: Neurocrine Biosciences Reports Second Quarter 2016 Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Neurocrine Biosciences Inc - Key Facts 6
Neurocrine Biosciences Inc - Key Employees 7
Neurocrine Biosciences Inc - Key Employee Biographies 8
Neurocrine Biosciences Inc - Major Products and Services 10
Neurocrine Biosciences Inc - Pharmaceutical Pipeline Products Data 11
Neurocrine Biosciences Inc, Pipeline Products by Therapy Area 11
Neurocrine Biosciences Inc, Pipeline Products by Development Phase 11
Neurocrine Biosciences Inc - History 13
Neurocrine Biosciences Inc - Company Statement 16
Neurocrine Biosciences Inc - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Section 2 – Company Analysis 20
Neurocrine Biosciences Inc - Business Description 20
Neurocrine Biosciences Inc - Corporate Strategy 21
Neurocrine Biosciences Inc - SWOT Analysis 22
SWOT Analysis - Overview 22
Neurocrine Biosciences Inc - Strengths 22
Neurocrine Biosciences Inc - Weaknesses 23
Neurocrine Biosciences Inc - Opportunities 24
Neurocrine Biosciences Inc - Threats 25
Neurocrine Biosciences Inc - Key Competitors 26
Section 3 – Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Neurocrine Biosciences Inc, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 36
Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 39
Dec 21, 2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down 40
Nov 02, 2016: Neurocrine Biosciences Reports Third Quarter 2016 Results 41
Aug 03, 2016: Neurocrine Biosciences Reports Second Quarter 2016 Results 44
May 20, 2016: Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors 46
May 05, 2016: Neurocrine Biosciences Reports First Quarter 2016 Results 47
Feb 11, 2016: Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 49
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55List of Tables
Neurocrine Biosciences Inc, Key Facts 6
Neurocrine Biosciences Inc, Key Employees 7
Neurocrine Biosciences Inc, Key Employee Biographies 8
Neurocrine Biosciences Inc, Major Products and Services 10
Neurocrine Biosciences Inc, Number of Pipeline Products by Development Stage 12
Neurocrine Biosciences Inc, History 13
Neurocrine Biosciences Inc, Subsidiaries 19
Neurocrine Biosciences Inc, Key Competitors 26
Neurocrine Biosciences Inc, Ratios based on current share price 27
Neurocrine Biosciences Inc, Annual Ratios 28
Neurocrine Biosciences Inc, Annual Ratios (Cont...1) 29
Neurocrine Biosciences Inc, Interim Ratios 31
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Neurocrine Biosciences Inc, Recent Deals Summary 35
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 54
Efficiency Ratios 54List of Figures
Neurocrine Biosciences Inc, Pipeline Products by Therapy Area 11
Neurocrine Biosciences Inc, Pipeline Products by Development Phase 11
Neurocrine Biosciences Inc, Performance Chart (2012 - 2016) 30
Neurocrine Biosciences Inc, Ratio Charts 32
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 34
Prometheus Laboratories Inc
Pfizer Inc
Newron Pharmaceuticals SpA
Lundbeck LLC
GlaxoSmithKline Inc
Eli Lilly and Company
Auspex Pharmaceuticals Inc
AbbVie Inc
